Vera Therapeutics (VERA) has shared an update.
Vera Therapeutics has appointed David Johnson, a seasoned biopharmaceutical executive with over two decades of industry experience, as their new Chief Operating Officer starting July 1, 2024. Johnson brings a wealth of knowledge from his previous roles, including his time as Chief Commercial Officer at Global Blood Therapeutics and various leadership positions at Gilead Sciences, where he successfully launched multiple drugs for liver diseases and HIV. As part of his compensation, Johnson will receive a $500,000 annual salary, eligibility for a 40% performance bonus, and stock options that vest over four years, with additional benefits in the event of a qualifying termination.
Learn more about VERA stock on TipRanks’ Stock Analysis page.
